Skip to content
Research peptides

N-Acetyl Semax and Selank Amidate: What the Modifications Change

N-acetylation and C-terminal amidation of Semax and Selank, explained: what each modification does chemically, what evidence exists, and common dosing.

Sebastian Hunter, Founder and EditorWritten bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

The short version

N-Acetyl Semax Amidate and N-Acetyl Selank Amidate have the same core heptapeptide sequences as Semax and Selank, with two changes. The N-terminus is capped (acetylation) and, in the "Amidate" forms, so is the C-terminus (amidation). Vendor and research-chemical education pages say the caps block the enzymes that normally chew a peptide apart from either end, so it lasts longer. I could not find a published human or animal study comparing the modified forms with plain Semax or Selank. The published research on both compounds used the unmodified sequence.

  • Acetylation caps the N-terminus; amidation caps the C-terminus. Neither changes the core amino-acid sequence responsible for the peptide's activity.
  • No published study I could locate compares N-Acetyl Semax Amidate or N-Acetyl Selank Amidate against the plain forms in humans or animals.
  • Research-chemical vendor and education pages describe the modified forms as longer-lasting, allowing less frequent dosing at similar per-dose amounts. That is a vendor claim, not a published finding.
  • Legal and evidence status tracks the parent compound. There is no separate regulatory or research picture from Semax and Selank.

“N-Acetyl Semax Amidate” and “N-Acetyl Selank Amidate” are the names most US research-chemical vendors now sell Semax and Selank under. Both names describe the same core heptapeptide with two added chemical caps, not a different peptide. This page covers what those two modifications do, what evidence compares the modified and unmodified forms, and what dosing information exists for the modified names.

US legal status - Research use only

No FDA-approved product exists under either name, in modified or unmodified form. Both are sold through research-chemical channels in the US; see the main Semax and Selank pages for the full legal picture.

What N-acetylation and C-terminal amidation change

A peptide chain has two ends. The N-terminus is a free amino group. The C-terminus is normally a free carboxylic acid, unless the synthesis adds an amide instead. Exopeptidases are enzymes that degrade peptides by chewing off one amino acid at a time from an end. They need that free, charged terminus to recognize where to start.

N-terminal acetylation attaches an acetyl group to the N-terminus. This neutralizes the charge that some of those enzymes need to begin. A 1991 paper on protein-sequencing methods notes that N-terminally acetylated peptides resist normal aminopeptidase processing. Unblocking them for lab sequencing takes a purpose-built enzyme, acylpeptide hydrolase (Farries 1991 - Farries TC, Harris A, Auffret AD et al. Removal of N-acetyl groups from blocked peptides with acylpeptide hydrolase. Stabilization of the enzyme and its application to protein sequencing. Eur J Biochem. 1991;196(3):679-85., in the references below). It shows how effectively the cap blocks the ordinary route in.

C-terminal amidation replaces the free carboxylic acid at the other end with an amide group. Modifying either terminus is a recognized general strategy for extending a peptide drug’s time in circulation, alongside approaches like PEGylation (Werle 2006 - Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351-67., in the references below).

Neither modification touches the internal amino-acid sequence that determines what a peptide binds to or how it acts. That sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro for Selank, and the ACTH(4-7)-derived sequence plus a Pro-Gly-Pro tail for Semax.

Research-chemical education pages that sell both forms make the same point. They say the acetyl cap on N-Acetyl Selank “removes the positive charge from the terminal amine, which means aminopeptidases can no longer recognize the site as a substrate.” The fully capped Amidate form adds an “amide group on the C terminus” as a second layer of protection, described as putting “bumpers on both ends of a pool lane” (FormBlends’ Selank N-Acetyl vs base comparison).

A parallel page on the Semax modifications says the single acetyl cap on plain N-Acetyl Semax blocks “the aminopeptidase side” while leaving “the proline end exposed” at the other terminus. The fully capped Amidate form adds a second cap there too (FormBlends’ Semax N-Acetyl Amidate vs base comparison). These are vendor and community education pages, not peer-reviewed sources.

What the published research actually covers

I could not find a published human or animal study that directly compares N-Acetyl Semax Amidate or N-Acetyl Selank Amidate against the plain, unmodified peptide. The research-chemical page that explains the Selank modification says so itself: “All of the published clinical research on Selank…used base Selank. Not the N Acetyl form. Not the Amidate” (FormBlends).

Its Semax counterpart says the same for Semax: “Almost all the published clinical research on Semax…used base Semax. That’s the molecule with the track record.” It adds that any study of the amidated variants covers “pharmacokinetic and stability grounds,” not clinical outcomes (FormBlends).

So every study behind the Semax and Selank evidence pages was conducted on the unmodified sequence. That is the Russian-language clinical literature this site already covers in full. None of it tested the acetylated or amidated forms now marketed under those names. Whether the modifications change the peptide’s effects in a person, beyond how long it persists, has not been tested either way.

N-Acetyl Semax Amidate and N-Acetyl Selank Amidate dosing

Research-chemical dosing guides on different sites describe a similar pattern for each modified form. None is a clinical source, and all describe common practice rather than an established dose.

N-Acetyl Semax Amidate:

  • One dosing guide describes starting at “600mcg-900mcg (2-3 pumps a day)” intranasally, for up to 30 days at the higher end or up to 60 days at 600 mcg/day. It notes that “research regarding N-Acetyl Semax Amidate administration in clinical settings is lacking” and that the figures are adapted from base-Semax protocols (Peptides.org).
  • A second guide lists protocols from 600 to 1,200 mcg/day, once or twice daily depending on the stated use case, with a “Typical Cycle: 10-30 days” (Professor Peptides).
  • A third describes the amidated form as “typically dosed once in the morning”, rather than the multiple daily doses base Semax protocols use (FormBlends).

N-Acetyl Selank Amidate:

  • One dosing guide describes “1 pump (300mcg) x2-3 times daily (total of 600-900mcg/daily)” intranasally for up to 14 days, followed by “at least a one-week break.” It states that “there are no official N-Acetyl Selank Amidate dosing guidelines” and that the figures are extrapolated from base-Selank practice (Peptides.org).
  • A second source describes the modified form as allowing twice-daily rather than three-times-daily dosing “at the same total” micrograms as base Selank. It gives no separate figures of its own (FormBlends).

No trial has established any of this, and no regulator has reviewed it. For the doses reported in the published research on the unmodified peptides, see Semax dosage and Selank dosage.

Neither modification changes the legal picture from the parent compound. See research peptides and US law and the FDA peptide regulation tracker for the general framework research-labeled peptides sit inside. The research-access supplier page explains how this site’s own supplier link works.

Common questions

What does N-Acetyl mean on a peptide label?

An acetyl group has been attached to the free amino group at the peptide's N-terminus (the start of the chain). That cap changes the chemistry of the terminal residue. Some enzymes that normally start eating a peptide from that end can no longer get a grip on it.

What does Amidate mean on a peptide label?

The peptide's C-terminus (the end of the chain) carries an amide group in place of the free carboxylic acid most synthesized peptides end in by default. Like N-terminal acetylation, it is a capping modification, aimed at the opposite end of the molecule.

Is N-Acetyl Semax the same as Semax?

It has the same core amino-acid sequence with an added N-terminal cap. Vendor pages selling both say the modification changes how long the peptide persists before being broken down, not the sequence responsible for its reported effects. No published study directly tested whether the two behave identically beyond that.

Is N-Acetyl Selank Amidate stronger than Selank?

Research-chemical education pages that discuss both forms describe them as comparable in acute effect at the same microgram dose. The modified form differs mainly in how long it lasts, not how strongly it acts. That is a vendor and community claim that no published trial has tested.

Is there research on N-Acetyl Semax or N-Acetyl Selank specifically?

I could not find any. The published clinical and preclinical literature on both Semax and Selank, including the trials this site cites elsewhere, used the unmodified heptapeptide. Claims about the acetylated and amidated forms come from vendor and research-chemical education pages describing pharmacokinetic reasoning and lab-scale stability. No published study covers the modified molecules themselves.

What is the common dose for N-Acetyl Semax Amidate?

Research-chemical dosing guides most often describe 600-900 mcg per day by intranasal spray, split across one to three administrations, in cycles of roughly 10-60 days. That is common practice reported by vendor and community sources, not a dose any trial or regulator has established. See the dosing detail below.

What is the common dose for N-Acetyl Selank Amidate?

Research-chemical dosing guides most often describe 600-900 mcg per day by intranasal spray, split across two or three administrations, in 14-day courses with at least a one-week break. That is common practice reported by vendor and community sources, not a dose any trial or regulator has established. See the dosing detail below.

References (7 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

  1. 1.Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351-67.ReviewPMID 16622600
  2. 2.Farries TC, Harris A, Auffret AD et al. Removal of N-acetyl groups from blocked peptides with acylpeptide hydrolase. Stabilization of the enzyme and its application to protein sequencing. Eur J Biochem. 1991;196(3):679-85.StudyPMID 2013290
  3. 3.FormBlends’ Selank N-Acetyl vs base comparison- formblends.comother
  4. 4.FormBlends’ Semax N-Acetyl Amidate vs base comparison- formblends.comother
  5. 5.Peptides.org- peptides.orgother
  6. 6.Professor Peptides- professorpeptides.coother
  7. 7.Peptides.org- peptides.orgother

Keep reading

Related guides